[1]王琼琼,赵胜.血小板活化在川崎病中的研究进展[J].心血管病学进展,2021,(6):552.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.000]
　WANG QiongqiongZHAO Sheng.Platelet Activation in the Pathogenesis of Kawasaki Disease[J].Advances in Cardiovascular Diseases,2021,(6):552.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.000]
点击复制

血小板活化在川崎病中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年6期
页码:
552
栏目:
综述
出版日期:
2021-06-25

文章信息/Info

Title:
Platelet Activation in the Pathogenesis of Kawasaki Disease
作者:
王琼琼 ;  赵胜
( 安徽医科大学,安徽 合肥 230051)
Author(s):
WANG QiongqiongZHAO Sheng
(Department of CardiologyAnhui Medical UniversityHefei 230051AnhuiChina )
关键词:
川崎病; 血小板活化; 冠状动脉损伤
Keywords:
Kawasaki Disease; Platelet Activation; Coronary Artery Lesion
DOI:
10.16806/j.cnki.issn.1004-3934.2021.08.000
摘要:
川崎病易导致儿童冠脉损伤。虽然该病至今原因不明，但近年研究表明血小板活化参与了川崎病的病理过程。现就血小板活化在川崎病中的研究进展做一综述。
Abstract:
Kawasaki disease is often complicated by coronary artery lesion in children. Its etiology is still unknown,but recent studies suggest that platelet activation is involved in the pathological process of Kawasaki disease. This article summarizes the research progress of platelet activation in the pathogenesis of Kawasaki disease

参考文献/References:

[1].Freedman JE. Molecular regulation of platelet-dependent thrombosis[J]. Circulation,2005,112(17):2725-2734.
[2].Levi M,van der Poll T,Bu?ller HR. Bidirectional relation between inflammation and coagulation[J]. Circulation,2004,109(22):2698-2704.
[3].Tamir A,Sorrentino S,Motahedeh S,et al. The macromolecular architecture of platelet-derived microparticles[J]. J Struct Biol,2016,193(3):181-187.
[4].Rossaint J,Margraf A,Zarbock A. Role of platelets in leukocyte recruitment and resolution of inflammation[J]. Front Immunol,2018,9:2712.
[5].McCrindle BW,Rowley AH,Newburger JW,et al. Diagnosis,treatment,and long-term management of kawasaki disease:a scientific statement for health professionals from the American Heart Association[J]. Circulation,2017,135(17):e927-e999.
[6].Jin J,Wang J,Lu Y,et al. Platelet-derived microparticles:a new index of monitoring platelet activation and inflammation in Kawasaki disease[J]. Indian J Pediatr,2019,86(3):250-255.
[7].Nomura S. Function and clinical significance of platelet-derived microparticles[J]. Int J Hematol,2001,74(4):397-404.
[8].Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery[J]. Hypertension,2004,43(2):428-433.
[9].Rossaint J,Kühne K, Skupski J,et al. Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune response[J]. Nat Commun,2016,7:13464.
[10].Arora K,Guleria S,Jindal AK,et al. Platelets in Kawasaki disease:Is this only a numbers game or something beyond?[J]. Genes Dis,2020,7(1):62-66.
[11].Kim HJ,Choi E,Lim YJ,et al. The Usefulness of Platelet-derived microparticle as biomarker of antiplatelet therapy in Kawasaki disease[J]. J Korean Med Sci,2017,32(7):1147-1153.
[12].Yahata T,Suzuki C,Yoshioka A,et al. Platelet Activation Dynamics Evaluated Using Platelet-Derived Microparticles in Kawasaki Disease[J]. Circulation Journal,2014:188-193.
[13].Lu Q,Malinauskas RA. Comparison of two platelet activation markers using flow cytometry after in vitro shear stress exposure of whole human blood[J]. Artif Organs,2011,35(2):137-144.
[14].Tong S,Wang H,Zhang T,et al. Accumulation of CD62P during storage of apheresis platelet concentrates and the role of CD62P in transfusion-related acute lung injury[J]. Mol Med Rep,2015,12(5):7777-7781.
[15].Dole VS,Bergmeie RW,Patten IS,et al. PSGL-1 regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets[J]. Thromb Haemost,2007,98(4):806-812.
[16].Liu G,Liang B,Song X,et al. P-selectin increases angiotensinⅡ-induced cardiac inflammation and fibrosis via platelet activation[J]. Mol Med Rep,2016,13(6):5021-5028.
[17].Tuan HTM,Hock LS,Abdullah ZW. Haemostatic parameters,platelet activation markers,and platelet indices among regular plateletpheresis donors[J]. J Taibah Univ Med Sci,2018,13(2):180-187.
[18].St John AE,Newton JC,Martin EJ,et al. Platelets retain inducible alpha granule secretion by P‐selectin expression but exhibit mechanical dysfunction during trauma‐induced coagulopathy[J]. J Thromb Haemost,2019,17(5):771-781.
[19].Burger PC,Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development[J]. Blood,2003,101(7):2661-2666.
[20].Collins RG,Velji R,Guevara NV,et al. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice[J]. J Exp Med,2000,191(1):189-194.
[21].郑晨,黎璇,丁粤粤,等. 川崎病患儿血小板表面PAC-1表达水平变化及意义[J]. 临床儿科杂志,2019,37(4):241-244.
[22].Inami N,Nomura S,Kikuchi H,et al. P-selectin and platelet-derived microparticles associated with monocyte activation markers in patients with pulmonary embolism[J]. Clin Appl Thromb Hemost,2003,9(4):309-316.
[23].Wang F,Wang L,Li Y,et al. PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway[J]. Eur J Pharmacol,2018,821:29-38.
[24].Jiang L,Ping L,Yan H,et al. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents:a special focus on definitions,diagnoses,mechanisms and management[J]. Expert Opin Drug Metab Toxicol,2020,16(9):823-835.
[25].Zhou Y,Wang S,Zhao J,et al. Correlations of complication with coronary arterial lesion with VEGF,PLT,D-dimer and inflammatory factor in child patients with Kawasaki disease[J]. Eur Rev Med Pharmacol Sci,2018,22(16):5121-5126.
[26].Carnevale R,Sciarretta S,Valenti V,et al. Low-grade endotoxaemia enhances artery thrombus growth via Toll-like receptor 4:implication for myocardial infarction[J]. Eur Heart J,2020,41(33):3156-3165.
[27].Marín Oyarzún CP,Glembotsky AC,Goette NP,et al. Platelet toll-like receptors mediate thromboinflammatory responses in patients with essential thrombocythemia[J]. Front Immunol,2020,11:705.
[28].Koupenova M,Clancy L,Corkrey HA,et al. Circulating platelets as mediators of immunity,inflammation,and thrombosis[J].Circ Res,2018,122(2):337-351.
[29].Trinchieri G,Sher A. Cooperation of Toll-like receptor signals in innate immune defence[J]. Nat Rev Immunol,2007,7(3):179-190.
[30].Kojok K,El-kadiry AE,Merhi Y. Role of NF-κB in platelet function[J]. Int J Mol Sci,2019,20(17):4185.
[31].Libby P. Inflammation in atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2012,32(9):2045-2051.
[32].Majdi F,Taheri F,SalehI P,et al. Cannabinoids Δ9-tetrahydrocannabinol and cannabidiol may be effective against methamphetamine induced mitochondrial dysfunction and inflammation by modulation of Toll-like type-4(Toll-like 4) receptors and NF-κB signaling[J]. Med Hypotheses,2019,133:109371.
[33].Wang M,Niu J,Ou L,et al. Zerumbone Protects against carbon tetrachloride (CCl4)-induced acute liver injury in mice via inhibiting oxidative stress and the inflammatory response:involving the TLR4/NF-κB/COX-2 pathway[J]. Molecules,2019,24(10):1964.
[34].Tülay Ayd?n P,G?z M,Kank?l?? N,et al. Micro-RNA gene expressions during cardiopulmonary bypass[J]. J Card Sur,2021,36(3):921-927.
[35].Parra-Izquierdo I,McCarty OJT,Aslan JE. Platelet miR-223 delivery rescues vascular cells in Kawasaki disease[J]. Circ Res,2020,127(7):874-876.
[36].Chu M,Wu R,Qin S,et al. Bone marrow-derived microRNA-223 works as an endocrine genetic signal in vascular endothelial cells and participates in vascular injury from Kawasaki disease[J]. J Am Heart Assoc,2017,6(2):e004878.
[37].Ning Q,Chen L,Song S,et al. The Platelet microRNA profile of Kawasaki disease:identification of novel diagnostic biomarkers[J]. Biomed Res Int,2020,2020:9061568.
[38].Wang B,Wang LN,Cheng FF,et al. MiR-222-3p in platelets serves as a distinguishing marker for early recognition of Kawasaki disease[J]. Front Pediatr,2019,7:237.
[39].Zhang Y,Wang Y,Zhang L,et al. Reduced platelet miR-223 induction in Kawasaki disease leads to severe coronary artery pathology through a miR-223/PDGFRβ vascular smooth muscle cell axis[J]. Circ Res,2020,127(7):855-873.

相似文献/References:

[1]杨再英,王钰.川崎病后无创检查评估血管内皮功能的研究进展[J].心血管病学进展,2019,(6):939.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.025]
　YANG Zaiying,WANG Yu.Non-invasive Assessment of Vascular Endothelial Function after Kawasaki Disease[J].Advances in Cardiovascular Diseases,2019,(6):939.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.025]
[2]石树文 田雯.肠道微生物群与儿童川崎病[J].心血管病学进展,2020,(6):608.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.012]
　SHI ShuwenTIAN Wen. Intestinal microbiota and children Kawasaki disease[J].Advances in Cardiovascular Diseases,2020,(6):608.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.012]
[3]张鹏 刘东升 张俊峰.血小板活化相关信号转导机制研究进展[J].心血管病学进展,2020,(10):1078.[doi:10.16806/j.cnki.issn.1004-3934.20.10.019]
　ZHANG Peng,LIU Dongsheng,ZHANG Junfeng.Signal Transduction Mechanism Related to Platelet Activation[J].Advances in Cardiovascular Diseases,2020,(6):1078.[doi:10.16806/j.cnki.issn.1004-3934.20.10.019]
[4]魏伟 魏灵睿 冷辉.血清miR-1和miR-26水平与川崎病患儿的关系及其对冠状动脉损伤的评估价值[J].心血管病学进展,2021,(5):476.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.021]
　WEI WeiWEI LingruiLENG Hui.Relationship Between Serum miR-1 and miR-26 Levels and Kawasaki Disease in Children and Its Value in Evaluating Coronary Artery Injury[J].Advances in Cardiovascular Diseases,2021,(6):476.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.021]
[5]李红霞 朱凯 刘雯 王慧 杨涛毅.0～5岁川崎病儿童静脉注射免疫球蛋白耐药的相关因素分析及预测模型构建[J].心血管病学进展,2023,(3):283.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.020]
　LI HongxiaZHU KaiLIU WenWANG HuiYANG Taoyi?/html>.Analysis of Related Factors and Prediction Model?f Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease Aged 0 5 Years[J].Advances in Cardiovascular Diseases,2023,(6):283.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.020]
[6]王慧 张燕平 王志强 陈桂华 谢江.基于孟德尔随机化探索肠道菌群与儿童川崎病之间的因果关系[J].心血管病学进展,2023,(6):572.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.020]
　WANG HuiZHANG Yanping,WANG Zhiqiang,CHEN Guihua,et al.To Explore the Causal Relationship Between Gut Microbiota and Kawasaki Disease in Children Based on Mendelian Randomization[J].Advances in Cardiovascular Diseases,2023,(6):572.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.020]

更新日期/Last Update: 2021-07-23